Literature DB >> 7810691

Role of CD11a and CD11b in ischemic acute renal failure in rats.

H Rabb1, C C Mendiola, J Dietz, S R Saba, T B Issekutz, F Abanilla, J V Bonventre, G Ramirez.   

Abstract

Leukocytes, particularly neutrophils, have been implicated in ischemic-reperfusion organ injury (IRI). However, their role in kidney IRI is controversial. Leukocytes express the adhesion molecules CD11/CD18 on their surface, which mediate many functions that can lead to tissue damage. To determine the role of CD11a and CD11b in IRI in the kidney, uninephrectomized Sprague-Dawley rats were pretreated with monoclonal antibodies (MAbs) directed against CD11a and CD11b or control MAbs. The serum creatinine (SCr), complete blood count, and kidney histopathological damage scores (PDS) (scale: 0-4) were assessed prior to and 24 h after 60 min of ischemia. Mean SCr 24 h after ischemia was significantly decreased in the anti-CD11a- and -CD11b-treated group compared with the control MAb-treated group (2.5 +/- 0.3 mg/dl vs. 3.4 +/- 0.2 mg/dl, P < 0.05). PDS were also reduced in the CD11a and CD11b group compared with controls (2.7 +/- 0.2 vs. 3.5 +/- 0.1, P < 0.001). These data show that the CD11/CD18 leukocyte adhesion pathway plays a role in mediating ischemic acute renal failure in rats.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7810691     DOI: 10.1152/ajprenal.1994.267.6.F1052

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  32 in total

Review 1.  Renal ischemia--reperfusion injury: an inescapable event affecting kidney transplantation outcome.

Authors:  R Böhmová; O Viklický
Journal:  Folia Microbiol (Praha)       Date:  2001       Impact factor: 2.099

2.  Toll-like receptor 4 regulates early endothelial activation during ischemic acute kidney injury.

Authors:  Jianlin Chen; Reji John; James A Richardson; John M Shelton; Xin J Zhou; Yanxia Wang; Qing Qing Wu; John R Hartono; Pamela D Winterberg; Christopher Y Lu
Journal:  Kidney Int       Date:  2010-10-06       Impact factor: 10.612

3.  Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1.

Authors:  Qing Qing Wu; Yanxia Wang; Martin Senitko; Colin Meyer; W Christian Wigley; Deborah A Ferguson; Eric Grossman; Jianlin Chen; Xin J Zhou; John Hartono; Pamela Winterberg; Bo Chen; Anapam Agarwal; Christopher Y Lu
Journal:  Am J Physiol Renal Physiol       Date:  2011-02-02

Review 4.  Ischemia-reperfusion and immediate T cell responses.

Authors:  Yanfei Huang; Hamid Rabb; Karl L Womer
Journal:  Cell Immunol       Date:  2007-10-17       Impact factor: 4.868

Review 5.  Immunologic research in kidney ischemia/reperfusion injury at Johns Hopkins University.

Authors:  Gang Jee Ko; Asif Zakaria; Karl L Womer; Hamid Rabb
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

6.  Identification of thrombospondin 1 (TSP-1) as a novel mediator of cell injury in kidney ischemia.

Authors:  Charuhas V Thakar; Kamyar Zahedi; Monica P Revelo; Zhaohui Wang; Charles E Burnham; Sharon Barone; Shannon Bevans; Alex B Lentsch; Hamid Rabb; Manoocher Soleimani
Journal:  J Clin Invest       Date:  2005-11-17       Impact factor: 14.808

Review 7.  Macrophages and immunologic inflammation of the kidney.

Authors:  Jeremy S Duffield
Journal:  Semin Nephrol       Date:  2010-05       Impact factor: 5.299

8.  The promise of immune cell therapy for acute kidney injury.

Authors:  Hamid Rabb
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

9.  The E-selectin ligand basigin/CD147 is responsible for neutrophil recruitment in renal ischemia/reperfusion.

Authors:  Noritoshi Kato; Yukio Yuzawa; Tomoki Kosugi; Akinori Hobo; Waichi Sato; Yuko Miwa; Kazuma Sakamoto; Seiichi Matsuo; Kenji Kadomatsu
Journal:  J Am Soc Nephrol       Date:  2009-05-14       Impact factor: 10.121

Review 10.  Leukocyte recruitment and acute renal failure.

Authors:  Kai Singbartl; Klaus Ley
Journal:  J Mol Med (Berl)       Date:  2003-12-10       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.